Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Proteomics International Laboratories stock

PIQ.AX
AU000000PIQ0

Price

0.66
Today +/-
-0.01
Today %
-1.50 %

Proteomics International Laboratories stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Proteomics International Laboratories stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Proteomics International Laboratories stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Proteomics International Laboratories stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Proteomics International Laboratories's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Proteomics International Laboratories Stock Price History

DateProteomics International Laboratories Price
11/26/20240.66 undefined
11/25/20240.67 undefined
11/22/20240.66 undefined
11/21/20240.68 undefined
11/20/20240.68 undefined
11/19/20240.71 undefined
11/18/20240.70 undefined
11/15/20240.71 undefined
11/14/20240.71 undefined
11/13/20240.74 undefined
11/12/20240.72 undefined
11/11/20240.71 undefined
11/8/20240.70 undefined
11/7/20240.70 undefined
11/6/20240.70 undefined
11/5/20240.69 undefined
11/4/20240.71 undefined
11/1/20240.73 undefined
10/31/20240.73 undefined
10/30/20240.71 undefined

Proteomics International Laboratories Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Proteomics International Laboratories, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Proteomics International Laboratories from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Proteomics International Laboratories’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Proteomics International Laboratories. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Proteomics International Laboratories’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Proteomics International Laboratories’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Proteomics International Laboratories’s growth potential.

Proteomics International Laboratories Revenue, EBIT and net profit per share

DateProteomics International Laboratories RevenueProteomics International Laboratories EBITProteomics International Laboratories Net Income
2027e9.8 M undefined-2.73 M undefined-1.32 M undefined
2026e6.36 M undefined-5.15 M undefined-3.97 M undefined
2025e3.13 M undefined-7.68 M undefined-6.62 M undefined
20241.41 M undefined-6.45 M undefined-6.38 M undefined
20231.47 M undefined-6.23 M undefined-6.18 M undefined
20221.72 M undefined-4.97 M undefined-4.97 M undefined
20211.47 M undefined-3.07 M undefined-2.86 M undefined
20201.61 M undefined-1.99 M undefined-1.74 M undefined
20191.52 M undefined-1.8 M undefined-2.08 M undefined
20181.2 M undefined-1.37 M undefined-1.44 M undefined
2017940,770 undefined-843,440 undefined-916,480 undefined
2016850,970 undefined-1.3 M undefined-1.33 M undefined
2015608,390 undefined-522,910 undefined-1.15 M undefined
2014480,000 undefined-220,000 undefined-250,000 undefined
2013680,000 undefined-210,000 undefined-250,000 undefined
2012590,000 undefined-40,000 undefined-160,000 undefined

Proteomics International Laboratories Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20122013201420152016201720182019202020212022202320242025e2026e2027e
0000001111111369
-------------200.00100.0050.00
----------------
0000000000000000
000-1-10-1-2-1-2-4-6-6-6-3-1
-------100.00-50.00100.00100.0050.00---50.00-66.67
65.4865.4865.4826.3450.5955.0760.6980.3387.42101.7105.53116.45125.85000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Proteomics International Laboratories Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Proteomics International Laboratories is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (k)PROVISIONS (k)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (k)DEBT (M)TOTAL CAPITAL (M)
2012201320142015201620172018201920202021202220232024
                         
0.050.050.0520.580.782.321.512.375.62.116.036.64
350250210195.78141.99317.86603.27464.92463.06258.58445.1186.21250.6
000000036.4893.4353.059.89145.2218.7
0000000000000
000.110.320.881.280.871.231.21.421.81.972.26
0.40.30.372.521.62.383.793.244.127.344.368.339.16
0.010.010.020.010.020.510.360.211.441.260.971.691.71
0000001.18000000
0000000000000
0001.011.011.011.011.011.011.011.011.011.01
0000000000000
000000160163.680059.5659.560
0.010.010.020.010.020.511.70.381.441.261.031.751.71
0.410.310.392.531.622.895.493.625.558.65.410.0810.88
                         
0.350.360.374.044.055.9410.3710.5413.3919.119.3430.1836.81
0000000000000
-0.77-1.03-1.28-2.24-3.26-4.33-5.69-7.55-8.95-11.49-15.95-21.8-27.4
0000000000000
0000000000000
-0.42-0.67-0.911.810.791.614.682.994.447.613.398.389.41
160230200275.02341.6314.82390.14224.76182142.27517.05154.3157.59
000000099.42110.53174.98000
0.150.110.0800.030.040.070.080.270.391.180.920.75
8060200000000000
0056000219.24147.5146.5963.869.05030.5495.36
0.390.40.860.280.370.580.610.550.620.781.71.10.91
450580440441.89441.89656.16164.9218.3369.040033.55221.04
0000000000000
00010.121.5544.342.2567.18425.3211.15300.59615.77499.89
450580440451.99463.44700.46207.1785.51494.34211.15300.59649.32720.93
0.840.981.30.730.831.280.820.631.120.9921.751.63
0.420.310.392.531.622.895.493.625.558.65.410.1311.04
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Proteomics International Laboratories provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Proteomics International Laboratories's financial health and stability.

Assets

Proteomics International Laboratories's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Proteomics International Laboratories must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Proteomics International Laboratories after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Proteomics International Laboratories's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (k)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (k)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020202120222023
000000000
000000000
000000000
000000000
000000000
000000000
000001,0001,0001,0001,000
0-1-1-1-10-2-3-5
00000-100-1
00000-100-1
000000000
000000000
000000000
3023035010
2012025010
---------
000000000
1,000-3,000-1,0000-3,00000-8,000-3,000
-0.68-1.52-1.62-1.13-1.71-1.97-2.41-3.67-6.91
000000000

Proteomics International Laboratories stock margins

The Proteomics International Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Proteomics International Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Proteomics International Laboratories.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Proteomics International Laboratories's sales revenue. A higher gross margin percentage indicates that the Proteomics International Laboratories retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Proteomics International Laboratories's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Proteomics International Laboratories's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Proteomics International Laboratories's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Proteomics International Laboratories. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Proteomics International Laboratories's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Proteomics International Laboratories Margin History

Proteomics International Laboratories Gross marginProteomics International Laboratories Profit marginProteomics International Laboratories EBIT marginProteomics International Laboratories Profit margin
2027e0 %-27.84 %-13.51 %
2026e0 %-80.95 %-62.38 %
2025e0 %-245.16 %-211.3 %
20240 %-457.63 %-452.33 %
20230 %-422.94 %-419.6 %
20220 %-288.25 %-288.36 %
20210 %-209.38 %-195.14 %
20200 %-123.39 %-108.26 %
20190 %-118.97 %-137.19 %
20180 %-114.18 %-119.7 %
20170 %-89.65 %-97.42 %
20160 %-153.01 %-156.11 %
20150 %-85.95 %-188.89 %
20140 %-45.83 %-52.08 %
20130 %-30.88 %-36.76 %
20120 %-6.78 %-27.12 %

Proteomics International Laboratories Stock Sales Revenue, EBIT, Earnings per Share

The Proteomics International Laboratories earnings per share therefore indicates how much revenue Proteomics International Laboratories has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Proteomics International Laboratories earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Proteomics International Laboratories's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Proteomics International Laboratories’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Proteomics International Laboratories's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Proteomics International Laboratories Revenue, EBIT and net profit per share

DateProteomics International Laboratories Sales per ShareProteomics International Laboratories EBIT per shareProteomics International Laboratories Earnings per Share
2027e0.07 undefined0 undefined-0.01 undefined
2026e0.05 undefined0 undefined-0.03 undefined
2025e0.02 undefined0 undefined-0.05 undefined
20240.01 undefined-0.05 undefined-0.05 undefined
20230.01 undefined-0.05 undefined-0.05 undefined
20220.02 undefined-0.05 undefined-0.05 undefined
20210.01 undefined-0.03 undefined-0.03 undefined
20200.02 undefined-0.02 undefined-0.02 undefined
20190.02 undefined-0.02 undefined-0.03 undefined
20180.02 undefined-0.02 undefined-0.02 undefined
20170.02 undefined-0.02 undefined-0.02 undefined
20160.02 undefined-0.03 undefined-0.03 undefined
20150.02 undefined-0.02 undefined-0.04 undefined
20140.01 undefined-0 undefined-0 undefined
20130.01 undefined-0 undefined-0 undefined
20120.01 undefined-0 undefined-0 undefined

Proteomics International Laboratories business model

Proteomics International Laboratories is one of the most popular companies on Eulerpool.com.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Proteomics International Laboratories Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Proteomics International Laboratories historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Proteomics International Laboratories shares outstanding

The number of shares was Proteomics International Laboratories in 2023 — This indicates how many shares 116.454 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Proteomics International Laboratories earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Proteomics International Laboratories's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Proteomics International Laboratories’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Proteomics International Laboratories's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Proteomics International Laboratories.

Proteomics International Laboratories shareholders

%
Name
Stocks
Change
Date
12.53187 % Lipscombe (Richard John)16,417,125-18/9/2024
6.03040 % FIL Investment Management (Hong Kong) Limited7,900,0007,900,0001/25/2024
2.94282 % Dunlop (Mary Gay)3,855,1883,855,1888/9/2024
1.63082 % Himstedt & Co Pty Ltd2,136,41708/9/2024
1.48775 % Randolph Resources Pty. Ltd.1,949,00008/9/2024
1.48283 % Van Dissel (Dirk Charles Hawker)1,942,547-343,2958/9/2024
1.40836 % Quintal Pty. Ltd.1,845,0001,055,0008/9/2024
1.35385 % Zimmer (Manfred)1,773,5831,773,5838/9/2024
1.14784 % Xylo Pty. Ltd.1,503,70008/9/2024
1.08394 % Floan (Lisa)1,420,00056,7658/9/2024
1
2

Proteomics International Laboratories Executives and Management Board

Mr. Vikesh Malik

Proteomics International Laboratories Chief Commercialisation Officer
Compensation 393,079

Dr. Richard Lipscombe

Proteomics International Laboratories Managing Director, Executive Director
Compensation 330,000

Ms. Jacqueline Gray

Proteomics International Laboratories Chief Financial Officer
Compensation 288,189

Mr. Neville Gardiner

Proteomics International Laboratories Non-Executive Independent Chairman of the Board
Compensation 175,954

Dr. Robyn Elliott

(52)
Proteomics International Laboratories Non-Executive Independent Director
Compensation 93,135
1
2
3

Most common questions regarding Proteomics International Laboratories

What is the P/E ratio of Proteomics International Laboratories 2024?

The Proteomics International Laboratories P/E ratio is -13.03.

What is the P/S ratio of Proteomics International Laboratories 2024?

The Proteomics International Laboratories P/S ratio is 58.92.

What is the Quality Investing of Proteomics International Laboratories?

The Quality Investing for Proteomics International Laboratories is 6/10.

What is the revenue of Proteomics International Laboratories 2024?

The Proteomics International Laboratories revenue is 1.41 M AUD.

How high is the profit of Proteomics International Laboratories 2024?

The Proteomics International Laboratories profit is -6.38 M AUD.

What is the business model of Proteomics International Laboratories

No history available for Proteomics International Laboratories.

What is the Proteomics International Laboratories dividend?

Proteomics International Laboratories pays a dividend of 0 AUD distributed over payouts per year.

How often does Proteomics International Laboratories pay dividends?

The dividend cannot currently be calculated for Proteomics International Laboratories or the company does not pay out a dividend.

What is the Proteomics International Laboratories ISIN?

The ISIN of Proteomics International Laboratories is AU000000PIQ0.

What is the Proteomics International Laboratories ticker?

The ticker of Proteomics International Laboratories is PIQ.AX.

How much dividend does Proteomics International Laboratories pay?

Over the past 12 months, Proteomics International Laboratories paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Proteomics International Laboratories is expected to pay a dividend of 0 AUD.

What is the dividend yield of Proteomics International Laboratories?

The current dividend yield of Proteomics International Laboratories is .

When does Proteomics International Laboratories pay dividends?

Proteomics International Laboratories pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Proteomics International Laboratories?

Proteomics International Laboratories paid dividends every year for the past 0 years.

What is the dividend of Proteomics International Laboratories?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Proteomics International Laboratories located?

Proteomics International Laboratories is assigned to the 'Health' sector.

Wann musste ich die Aktien von Proteomics International Laboratories kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Proteomics International Laboratories from 11/28/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 11/28/2024.

When did Proteomics International Laboratories pay the last dividend?

The last dividend was paid out on 11/28/2024.

What was the dividend of Proteomics International Laboratories in the year 2023?

In the year 2023, Proteomics International Laboratories distributed 0 AUD as dividends.

In which currency does Proteomics International Laboratories pay out the dividend?

The dividends of Proteomics International Laboratories are distributed in AUD.

All fundamentals about Proteomics International Laboratories

Our stock analysis for Proteomics International Laboratories Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Proteomics International Laboratories Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.